Aseptically Prepared Systemic Anti-Cancer Treatment (SACT)
The value below is a framework or dynamic market ceiling: the maximum
that could be spent across all call-offs, not the value of a single contract.
Aggregate figures on this site exclude these to avoid double counting.
key details
| Status | complete |
|---|---|
| Category (CPV) | 33600000 |
| Region | Wales |
| Deadline | 4 Mar 2024 |
| Procedure | open |
| OCID | ocds-h6vhtk-04368a |
Awards (6)
This procurement was awarded to 6 suppliers. Values shown are per-award; the notice total is ·.
| Supplier | Value | Date | Status |
|---|---|---|---|
| Baxter Healthcare Limited shared | · | · | active |
| ITH Pharma Ltd shared | · | · | active |
| Lloyds Pharmacy Clinical Homecare shared | · | · | active |
| Qualasept Ltd t/a Bath ASU shared | · | · | active |
| Quantum Pharmaceutical Ltd shared | · | · | active |
| Sciensus Ltd shared | · | · | active |
description
NHS Wales Framework Agreement for the supply of Aseptically Prepared Systemic Anti-Cancer Treatment (SACT)
notice history
2 notices published against this procurement.
| Published | Type | Regime | Notice |
|---|---|---|---|
| 1 Feb 2024 | Contract notice (F02) | Earlier regulations | 003439-2024 |
| 9 Aug 2024 | Contract award notice (F03) | Earlier regulations | 025276-2024 |
more from Velindre NHS Trust, NHS Wales Shared Services Partnership - Procurement Services (on behalf of All Wales LHB's and Trusts)
- Unlicensed Medicines - Imports & Specials · 20 Jan 2025
- Generic Anti-Infective Drugs · £3,390,876 · 19 Mar 2024
- Licensed Bulk Medicines · £42,317,737 · 9 Jun 2023
- Lenalidomide · 9 Dec 2022
- Transitional Drugs · 11 Oct 2022
- Generic Drugs - Injections/Infusions · 3 Aug 2022
- Proprietary Drugs · 14 Jul 2022
- Generic Drugs - Tablets & Capsules · 7 Mar 2022
all contracts from this buyer →
similar contracts awarded
Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.
- Radiopharmaceutical Products - Poltech · The Christie NHS Foundation Trust · £39,000
- NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026 · NHS England · £592,363,416
- NHS National Generics Pharmaceuticals - Supply Chain Resilience · NHS England · £52,447,296
- Generic, Branded Generic & Proprietary Medicinal Products - Group 18 · Regional Business Services Organisation, Procurement and Logistics Service · £1,800,000,000
- Generic Drugs – Injections/Infusions 2 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £6,535,850
- Transitional Drugs 7 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £53,566,932
- NP90726m Vedolizumab (Entyvio®) · The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland) · £47,898,609
- Combined Needles and Syringes Lot 1 · Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency · £15,264,000
source
Published on Find a Tender. Contact details for named individuals are not reproduced on this site.